Enterprise Value to EBITDA Ratio: Delcath Systems, Inc. (DCTH)
The price trajectory for Delcath Systems, Inc. (DCTH) shown below is based on the EV/EBITDA multiple, which currently stands at 0.00. The business relies on creating a closed interventional oncology ecosystem around the CHEMOSAT complex, requiring clinics to adhere to strict brand standards. The team is aggressively promoting the HEPZATO KIT and expanding the application of its developments, demonstrating persistence in commercialization and regulatory advancement.
delcath.com - analytical breakdowns and key metrics (DCTH)
- current price and projected stock value:
- company stock exchange capitalization indicators:
- business book valuation details:
- issuer credit burden and liquidity indicators:
- business earnings and investment ratios data:
DCTH - Net Profit|Future Profit Delcath Systems, Inc.|DCTH - Market Price to Net Income Ratio|Forward P/E Multiple Delcath Systems, Inc.|DCTH - Growth-Adjusted Payback Ratio|Enterprise Value to EBITDA Ratio Delcath Corp|DCTH - Income before deduction of interest, taxes and amortization|Earnings per share for the last twelve months Delcath Systems|DCTH - Net earnings per share for the last four quarters|Year-over-year net earnings per share growth for the last 12 months delcath.com|DCTH - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year Delcath Systems, Inc.
Initial company analysis:DCTH (Delcath)
The EV/EBITDA multiple compares the total enterprise value, including debt, with its operating profit before taxes, depreciation, and amortization. For Delcath Systems, Inc. (DCTH), which is developing liver chemotherapy systems, this metric reflects capitalization efficiency amid the diversification of oncology programs. The current value of 0.00 within the EV/EBITDA multiple trend helps determine the fair value of assets. This metric serves as a fundamental filter to separate market noise from the company's actual resilience.
Who Delcath Systems, Inc. competes with
EV/EBITDA Multiple ONC (BeiGene Corp)|HALO - Enterprise Value to EBITDA Ratio|RVMD: Enterprise Value to EBITDA Ratio|AAPG - EV/EBITDA Multiple|CG Oncology (CGON) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|UroGen Pharma Ltd - Business Value to Operating Income Before Depreciation|BCAX (Bicara Bio) - EV/EBITDA Multiple|Company Value to EBITDA Personalis Genomics PSNL|EV/EBITDA Multiple ERAS|ymabs.com - Enterprise Value to Operating Income Before Depreciation|EV/EBITDA Multiple AURA (Aura Biosciences)|Candel Therapeutics Inc. (CADL) - Company Value to EBITDA|ARAY - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|SLS: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|ACTU: EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio citiusonc.com|HURA (TuHURA Biosciences Inc.) - EV/EBITDA Multiple|EV/EBITDA Multiple Protara Therapeutics Inc|Enterprise Value to EBITDA Ratio FATE (Fate Therapeutics Corp)|Enterprise Value to Operating Income Before Depreciation Ratio WHWK|EV/EBITDA Multiple TCRX (TScan Therapeutics, Inc.)|Business Value to Operating Income Before Depreciation CSBR|XBIT: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation CVM (CEL-SCI Corporation)|OS Therapies Inc (OSTX) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|RADX - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to EBITDA Ratio ARTV|Company Value to EBITDA Adlai Nortye Limited ANL|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Veru (VERU)|Total Company Value to Operating Income Before Depreciation Ratio Tempest Therapeutics Inc|Xilio Therapeutics - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation Ratio RENB (Renovaro Biosciences)|Mural Bio - EV/EBITDA Multiple|Company Value to EBITDA Kairos Pharma Ltd|onkuretherapeutics.com (OKUR) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio CytoMed Therapeutics Limited|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Curis Inc.|Apollomics Corp (APLM) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to EBITDA Ratio THAR (Tharimmune, Inc.)|ADVB (advanbiomed.com) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple GNPX (Genprex)|Total Company Value to Operating Income Before Depreciation Ratio Calidi Biotherapeutics Inc. (CLDI)|SBFM - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|XBIO (Xenetic Biosciences) - Enterprise Value to Operating Income Before Depreciation|SLRX: EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio purple-biotech.com|Enterprise Value to EBITDA Ratio AONC|BeiGene Ltd. (BGNE) - Total Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple CKPT|Elevation Oncology Inc. - Enterprise Value to Operating Income Before Depreciation|EV/EBITDA Multiple ICAD (iCAD)|IKNA - Enterprise Value to EBITDA Ratio|NTBL: Enterprise Value to EBITDA Ratio|Viracta Therapeutics - Enterprise Value to Operating Income Before Depreciation Ratio|MOR: EV/EBITDA Multiple|NAYA Biosciences Corp - Business Value to Operating Income Before Depreciation|AAPGV (Ascentage Pharma Group) - EV/EBITDA Multiple
